Molecular Templates, Inc. Announces Pricing of $75.9 Million Public Equity Offering Feb 18, 2021 7:30am EST
Molecular Templates Establishes Multi-Target Collaboration With Bristol Myers Squibb for the Discovery and Development of Next Generation Engineered Toxin Bodies for the Treatment of Cancer Feb 11, 2021 7:30am EST
Molecular Templates Announces FDA Acceptance of IND Application for MT-6402, a PD-L1-Targeted Engineered Toxin Body Enabled with Proprietary Antigen Seeding Technology Jan 19, 2021 8:00am EST
Molecular Templates, Inc. Reports Third Quarter 2020 Financial Results and Provides a Corporate Update Nov 05, 2020 4:30pm EST
